trial

Pediatric Open-Label Extension Study

NCTId NCT01914393
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 702 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2018-10-17
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
702 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2013-09-30
Primary completion
2018-10-17
Eligibility
ALL · 6 Years · 17 Years

Interventions & indications

Drugs
Lurasidone

Sponsors

Sumitomo Pharmaceuticals AmericaLead Sponsor

Investigators

1
Lurasidone Medical Director, MDStudy Director

Sites

88 total
Dothan, United StatesDowney, United StatesSan Francisco, United StatesSanta Ana, United StatesGainesville, United StatesOrlando, United StatesOrlando, United StatesSanford, United StatesSt. Petersburg, United StatesTampa, United StatesAtlanta, United StatesSmyrna, United States

Linked catalysts

1
Pediatric Open-Label Extension Study — primary completion2018-10-17

Facts & assertions

4 sourced
Enrollment
702
Phase
PHASE3
Primary Completion Date
2018-10-17
Status
COMPLETED
relationships
The graph out of here
drug
Lurasidone
drug
lead_sponsor
Sumitomo Pharmaceuticals America
company
indication
Bipolar Disorder
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Lurasidone Medical Director, MD
person